In conclusion, increased numbers of TIGIT+ T cells were correlated with inferior outcomes and poor survival and the blockade of TIGIT signaling may have therapeutic potential for patients with follicular lymphoma. The gene discussed is TIGIT; the disease is follicular lymphoma.